Through its unique ability to mimic nature, PepMetics® Technology unlocks undruggable targets.

In-house Pipelines:
PRISM originates programs for novel targets and bring to clinical candidates and license to pharma.

Platform Collaborations:
PRISM provides drug discovery platform to generate hit compounds for partner’s targets.

  • HTML5
  • CSS3 & SCSS & CSS in JS
  • JavaScript
  • jQuery
  • NodeJS
  • Grunt / Gulp / Webpack
  • Grunt / Gulp / Webpack
  • Grunt / Gulp / Webpack
  • Grunt / Gulp / Webpack
  • Ono

FEP: Cancer
Part of In-house program - Seeking Collaboration

FEP633, A Novel Binding Inhibitor of eIF4E/eIF4G1

  • 4E-BP1 is a repressor protein of eIF4E.  Along with phosphorylation of 4E-BP1 via mTORC1, eIF4E is unbonded from 4E-BP1 and binds to eIF4G1.  This is a critical path to initiate CAP dependent translation
  • It has been reported advanced tumors often show higher expressions of phosphorylated 4E-BP1
  • FEP600 is a mimetic compound to 4E-BP1 and suppresses eIF4E binding to eIF4G1
  • FEP633 is a prodrug of FEP600 at the final stage of lead optimization

With PDX models derived from urothelial carcinoma, FEP600 was shown to be more efficacious than Cisplatin, the current Standard of Care.

Muscle Invasive Urothelial Carcinoma with lower expressions of Ser-65 Phosphorylated 4E-BP1

Metastatic Urothelial Carcinoma with higher expressions of Ser-65 Phosphorylated 4E-BP1